| Mar 18, 2025 |
Researchers developed an innovative nano-immune agonist that significantly improves immunotherapy outcomes for melanoma – a highly aggressive and hard-to-treat form of skin cancer.
(Nanowerk News) Prof. WU Zhengyan from the Hefei Institutes of Physical Science of the Chinese Academy of Sciences, in collaboration with Prof. ZHANG Guilong from Binzhou Medical University, has developed an innovative nano-immune agonist that significantly improves immunotherapy outcomes for melanoma—a highly aggressive and hard-to-treat form of skin cancer.
|
|
The study, published in Journal of Colloid and Interface Science (“Biodegradable nano-immune agonist for enhanced immunotherapy of melanoma via the synergistic action of cuproptosis and cGAS-STING enhanced immune response”), introduces a biodegradable therapeutic nanomaterial called pLCGM-OVA.
|
 |
| Schematic illustration of the preparation route and anti-tumor mechanism of pLCGM-OVA. (Image: LI Qingdong) (click on image to enlarge)
|
|
Melanoma remains a clinical challenge largely due to its strong immunosuppressive tumor microenvironment, which weakens the effectiveness of conventional immune checkpoint inhibitors. To overcome this hurdle, the researchers designed a multifunctional nanoplatform capable of reshaping the tumor microenvironment and enhancing the body’ s natural immune defense against cancer.
|
|
To address this issue, the team designed and synthesized a safe and efficient nano-immune agonist. It works through a combination of mechanisms: it induces immunogenic cell death via reactive oxygen species and copper-triggered cuproptosis—a newly recognized form of regulated cell death.
|
|
Additionally, it incorporates ovalbumin (OVA) as a model antigen to boost vaccine-like immune responses, and importantly, it activates the cGAS-STING signaling pathway, a key player in innate immune activation. Together, these effects stimulate a strong anti-tumor immune response, effectively suppressing both melanoma growth and recurrence.
|
|
Beyond its therapeutic capabilities, pLCGM-OVA also serves as a T1-weighted magnetic resonance imaging (MRI) contrast agent, enabling simultaneous diagnosis and treatment—a promising step toward advanced cancer theranostics.
|
|
This research marks a significant advancement in nanomedicine and cancer immunotherapy, offering new hope for more effective melanoma treatments.
|
